Please read and agree to the terms and conditions of this site.
@xconomy.com 4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com 4 years ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com 4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com 4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com 4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com 4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com 4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com 4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com 4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com 4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com 4 years ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com 4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com 4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com 4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com 4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com 4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com 4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com 4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com 4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com 4 years ago
White House Floats Canadian Import Plan But Excludes Many Costly Drugs
@xconomy.com 4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com 4 years ago
San Antonio to Honor Regenerative Medicine Pioneer Stephen Badylak
@xconomy.com 4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com 4 years ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com 4 years ago
Boston Tech Watch: Vaxess, Fusion Power, Wayfair & MassChallenge
@xconomy.com 4 years ago
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome
@xconomy.com 4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com 4 years ago
Review: Inside the House of Lies at Theranos
@xconomy.com 4 years ago
Boston Tech Watch: Polaris, GE, DataRobot, Facial Recognition Woes
@xconomy.com 4 years ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
@xconomy.com 4 years ago
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes
@xconomy.com 4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com 4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com 4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com 4 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com 5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com 5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com 5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com 5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com 5 years ago
Roswell, Organovo & More: Xconomy Awards Innovation at the Intersection Finalists
@xconomy.com 5 years ago
Censinet Takes Off With $7.8M to Track Cyber Risks in Healthcare
@xconomy.com 5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com 5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com 5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com 5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com 5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com 5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take